Details for Patent: 10,786,501

Which drugs does patent 10,786,501 protect, and when does it expire?

Patent 10,786,501 protects ORGOVYX and is included in one NDA.

This patent has sixty-one patent family members in twenty-four countries.

Summary for Patent: 10,786,501

Title:	Treatment of prostate cancer
Abstract:	Methods for treating prostate cancer, including advanced prostate cancer, in a subject in need thereof, include administering once-daily to the subject, at least 80 mg of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyr- idazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-- N'-methoxyurea, or a corresponding amount of a pharmaceutically acceptable salt thereof. Another method includes: administering once-daily to the subject in need thereof, an oral load dose formulation having from 240 mg to 480 mg of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyr- idazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-- N'-methoxyurea, or a corresponding amount of a pharmaceutically acceptable salt thereof; and thereafter administering once-daily to the subject, an oral maintenance dose formulation having 80 mg to 160 mg of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyr- idazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-- N'-methoxyurea, or a corresponding amount of a pharmaceutically acceptable salt thereof.
Inventor(s):	Rajasekhar; Vijaykumar Reddy (Apple Valley, CA), Johnson; Brendan Mark (Chapel Hill, NC), MacLean; David B. (Cambridge, MA), Seely; Lynn (San Mateo, CA), Mudd, Jr.; Paul N. (Cary, NC)
Assignee:	Myovant Sciences GmbH (Basil, CH) Takeda Pharmaceutical Company Limited (Osaka, JP)
Application Number:	16/563,161
Patent Claim Types: see list of patent claims	Use; Formulation;

Drugs Protected by US Patent 10,786,501

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Sumitomo Pharma	ORGOVYX	relugolix	TABLET;ORAL	214621-001	Dec 18, 2020		RX	Yes	Yes						TREATMENT OF ADULT PATIENTS WITH ADVANCED PROSTATE CANCER

International Family Members for US Patent 10,786,501

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	109759
Argentina	109762
Argentina	110636